New drug combo aims to outsmart resistant lung cancer
NCT ID NCT07315113
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-phase trial tests a new oral drug called NXP900 combined with the standard drug osimertinib in 18 adults with advanced EGFR-mutated non-small cell lung cancer that has progressed on prior osimertinib. The main goals are to check safety and see if the combination can shrink tumors or control the disease. Because it is a Phase 1 study, the focus is on finding the right dose and watching for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Massachusetts General Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NXP900 combined with osimertinib
What this could lead to
If it works, this could point toward a new combination treatment for advanced EGFR-mutated lung cancer that has stopped responding to osimertinib alone.
What could go wrong
This is a very early Phase 1b trial with only 18 participants, so it is primarily testing safety and dosing. The combination may not shrink tumors or may cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.